Ipsen has presented long-awaited phase three results for elafibranor, a new class of medication for Primary Biliary Cholangitis. The disease, a genetic chronic liver condition, primarily affects women. Symptoms, which can take years to present, include fatigue and joint pain. Ipsen’s Jennifer Schranz noted that 51% of patients involved in the ELATIVE trial experienced significant benefits compared to 4% taking a placebo.
Implementing NIST CSF 2.0 A Technical Blueprint
NIST released the Cybersecurity Framework (CSF) 2.0 in February 2024, marking its first major update since 2014. Key enhancements include the new “Govern” function, revamped
.webp?w=0&resize=0,0&ssl=1 "Zero Trust Architecture Building Resilient Defenses for 2025")